Received Jun 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
marbled bluish red skin condition - diagnosed with Cutis Marmorata; consistent fever of 102 at night; This spontaneous report was received from a Nurse via company representative on 30-May-2025 concerning to her daughter a 1-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 23-May-2025,reported as a week ago, the patient was vaccinated with a first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II)(lot # ,expiration date, dose, and route were not reported) and with sterile diluent (MERCK STERILE DILUENT)(lot # , expiration date, dose, and route of administration were not reported) for prophylaxis. On 24-May-2025, the patient experienced consistent fever of 102 at night despite Motrin and marbled bluish red skin condition. The Child was seen in the emergency department last night, on 29-MAY-2025 and was diagnosed with Cutis Marmorata. At the reporting time, the outcome of marbled bluish red skin condition/diagnosed with Cutis Marmorata and consistent fever of 102 at night was unknown. The causality between the event events, Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II and with sterile diluent (MERCK STERILE DILUENT) was unspecified.